share_log

COSCIENS Biopharma Announces Change to Board of Directors

COSCIENS Biopharma Announces Change to Board of Directors

COSCIENS生物制药宣布董事会成员变动
GlobeNewswire ·  10/08 19:30

TORONTO, ONTARIO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) ("COSCIENS" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today announced the resignation of Carolyn Egbert from the Board of Directors, effective immediately.

多伦多,安大略省,2024年10月08日(全球新闻社)--COSCIENS生物制药公司(纳斯达克:CSCI)(tsx:CSCI)("COSCIENS"或"公司"),一家专业的生物制药公司,致力于开发和销售多样化的化妆品、保健品和药品产品,今天宣布卡罗琳·埃格伯特(Carolyn Egbert)立即辞去董事会成员职务。

"We are extremely grateful to Carolyn for her twelve years of dedicated service to the Company as a member of the Board of Directors, including serving eight years as Chair. Throughout her tenure as a board member of Aeterna Zentaris, now CONSCIENS, she provided valuable contributions and insight," said Chair of the Board, Ronald Miller. "With Carolyn's decision to resign from the Board and as the Company continues to evolve at various levels, we have made the strategic decision to streamline our board structure and move forward with six members, including five independent directors which we believe more closely aligns with the industry standard for a Company at our stage."

"我们对卡罗琳在公司担任董事会成员十二年的辛勤服务表示衷心感谢,其中包括担任八年的主席。作为依特钠(Aeterna Zentaris)董事会成员,现已更名为康思生物(CONSCIENS),她提供了宝贵的贡献和见解,"董事长罗纳德·米勒(Ronald Miller)表示。"随着卡罗琳决定辞去董事会职务,公司在各个层面持续发展的同时,我们已经做出战略决定优化董事会结构,并继续由六位成员前行,其中包括五位独立董事,我们相信这更符合我们这个阶段公司的行业标准。"

About COSCIENS Biopharma Inc.

关于COSCIENS生物制药公司

COSCIENS is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of significant unmet medical need. One of COSCIENS' lead products is macimorelin (Macrilen; Ghryvelin), the first and only U.S. FDA and European Medicines Agency approved oral test indicated for the diagnosis of adult growth hormone deficiency ("AGHD"). COSCIENS is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources currently used in cosmeceutical products (i.e., oat beta glucan and avenanthramides which are found in leading skincare product brands like Aveeno and Burt's Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

COSCIENS是一家专业的生物制药公司,致力于开发和销售包括专注于重大医疗需求领域的药品和诊断产品在内的多样化产品组合。 COSCIENS的主要产品之一是马西莫列林(Macrilen; Ghryvelin),这是首个也是唯一获得美国FDA和欧洲药品管理局批准用于诊断成人生长激素缺乏症("AGHD")的口服测试。 COSCIENS还致力于开发治疗资产和专有的提取技术,该技术应用于从可再生植物资源中提取活性成分,目前已用于生产美容保健产品(例如燕麦β-葡聚糖和燕麦甙素,这些成分被用于领先的护肤产品品牌,如雅漾和巴特蜜的配方)并正在开发为潜在的保健品和/或药品。

The company is listed on the NASDAQ Capital Market and the Toronto Stock Exchange, and trades on both exchanges under the ticker symbol "CSCI". For more information, please visit COSCIENS' website at .

该公司在纳斯达克资本市场和多伦多证券交易所上市,并在两个交易所上以"CSCI"为股票代码交易。更多信息,请访问COSCIENS的网站。

Forward-Looking Statements

前瞻性声明

The information in this news release has been prepared as of October 1, 2024. Certain statements in this news release, referred to herein as "forward-looking statements", constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended, and "forward-looking information" under the provisions of Canadian securities laws. All statements, other than statements of historical fact, that address circumstances, events, activities, or developments that could or may or will occur are forward-looking statements. When used in this news release, words such as "anticipate", "assume", "believe", "could", "expect", "forecast", "future", "goal", "guidance", "intend", "likely", "may", "would" or the negative or comparable terminology as well as terms usually used in the future and the conditional are generally intended to identify forward-looking statements, although not all forward-looking statements include such words.

本新闻稿中的信息截至2024年10月1日已经准备好。本新闻发布中的某些陈述,即所谓的“前瞻性陈述”,构成1995年修正的美国《证券诉讼改革法案》和《加拿大证券法》条款下的“前瞻性信息”。所有陈述,除了回顾事实的陈述之外,涉及可能发生的情况、事件、活动或发展的陈述都属于前瞻性陈述。在本新闻中使用时,“预期”、“假设”、“相信”、“可能”、“期望”、“预测”、“未来”、“目标”、“引导”、“打算”、“可能”、“会”等词语或其负面或可比较的术语以及通常用于未来和假设条件的词汇通常用于识别前瞻性陈述,尽管并非所有前瞻性陈述都包含这些词语。

Forward-looking statements are necessarily based upon a number of factors and assumptions that, while considered reasonable by the Company as of the date of such statements, are inherently subject to significant business, economic, operational and other risks, uncertainties, contingencies and other factors, including those described below, which could cause actual results, performance or achievements of the combined Company to be materially different from results, performance or achievements expressed or implied by such forward-looking statements and, as such, undue reliance must not be placed on them.

前瞻性声明必须基于多个因素和假设,尽管截至声明日公司认为这些声明合理,却天然受到重大的业务、经济、运营和其他风险、不确定性、偶发事项和其他因素的影响,包括以下因素,因此不应过度依赖这些声明。这些风险和不确定性包括但不限于:合并后公司的现有和未来业务战略;运营人绩在预期范围内;预期未来现金流;合并后公司所处的当地和全球经济情况和环境;预期的资本和运营费用;产品开发和相关临床试验和验证研究中的不确定性,包括我们对于美国食品药品监督管理局和欧盟的儿童临床试验的成功依赖性以及DETECt-试验的结果可能不支持在儿童成长激素缺乏症的监管批准申请;马克莉伦(马西莫林)由昆士兰大学或为我们开发的其他产品的正在进行或计划中的临床前研究的结果可能不成功或可能不支持将产品推向人类临床试验;我们筹集资本和获得融资以继续我们目前计划中的业务;我们现在严重依赖马西莫林(马西莫林)的成功和相关的外部许可安排以及成功商业化产品所需的资金和资源的持续可用性;确保拥有后期开发、营销和分销伙伴,其中包括我们能否在与Novo Nordisk AG终止许可协议后达成新的许可协议或类似安排;我们进入与其他制药公司的许可、开发、制造、营销和分销协议的能力,并使这些协议继续有效;保护和执行我们的专利组合和知识产权的能力;以及我们继续在纳斯达克上市我们的普通股的能力。

Forward-looking statements involve known and unknown risks and uncertainties which include, among others: the combined Company's present and future business strategies; operations and performance within expected ranges; anticipated future cash flows; local and global economic conditions and the environment in which the combined Company operates; anticipated capital and operating costs; uncertainty in our revenue generation from our marketed products, product development and related clinical trials and validation studies; results from our products under development may not be successful or may not support advancing the product; the failure of the DETECT-trial to achieve its primary endpoint in Childhood Growth Hormone Deficiency may impact the market for macimorelin (Macrilen; Ghryvelin) in AGHD and the existing relationships we have for that product; ability to raise capital and obtain financing to continue our currently planned operations; our now heavy dependence on sales by and revenue from our main distributor of our legacy Ceapro products and its customers, the continued availability of funds and resources to successfully commercialize our products; the ability to secure strategic partners for late stage development, marketing, and distribution of our products; our ability to enter into out-licensing, development, manufacturing, marketing and distribution agreements with other pharmaceutical companies and keep such agreements in effect; our ability to protect and enforce our patent portfolio and intellectual property; and our ability to continue to list our common shares on the NASDAQ Capital Market.

展望性声明涉及已知和未知的风险与不确定因素,包括但不限于:合并公司的当前和未来业务战略;运营和绩效在预期范围内;预期未来现金流;合并公司运营环境中的本地与全球经济情况;预期资本支出与运营成本;我们从已投放市场产品、产品研发和相关临床试验及验证研究中的营业收入产生不确定性;我们正在研发的产品可能在临床试验中失败或无法支持产品推进;DETECt-试验未能达到童年生长激素缺乏症的主要终点可能影响马西莫林(Macrilen; Ghryvelin)在生长激素成人缺乏症的市场和我们为该产品建立的现有关系;筹集资金并获取融资以继续我们目前计划的业务;我们目前对遗产Ceapro产品的主要经销商及其客户销售的依赖程度加重,成功商业化我们的产品所需资金和资源的持续可用性;寻求后期开发、营销和分销战略合作伙伴的能力;与其他制药公司签订外部授权、研发、制造、营销和分销协议并保持此类协议的有效性的能力;保护和执行我们的专利组合和知识产权的能力;以及我们继续在纳斯达克资本市场上市我们的普通股的能力。

Investors should consult our quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties, including those discussed in our Annual Report on Form 20-F and MD&A filed under the Company's profile on SEDAR+ at and on EDGAR at www.sec.gov. We disclaim any obligation to update any such risks or uncertainties or to publicly announce any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or applicable law.

投资者应查阅我们在加拿大和美国证券委员会的季度和年度申报以获取有关风险和不确定性的其他信息,包括我们在SEDAR+公司档案中的20-F表格年度报告和MD&A,以及在www.sec.gov的EDGAR上。我们不承担更新任何此类风险或不确定性或公开宣布本文中包含的任何前瞻性声明的任何修订的义务,以反映未来结果、事件或发展,除非政府机关或适用法律要求这样做。

No securities regulatory authority has either approved or disapproved of the contents of this news release. The Toronto Stock Exchange accepts no responsibility for the adequacy or accuracy of this news release.

没有证券监管机构已经核准或驳回本新闻稿的内容。多伦多证券交易所对本新闻稿的充分性或准确性概不负责。

Issuer:
Gilles R. Gagnon
President & CEO
ggagnon@ceapro.com
+1 (780) 421-4555

发行人:
吉尔·加尼昂
总裁兼首席执行官
ggagnon@ceapro.com
+1 (780) 421-4555

Investor Contact:
Jenene Thomas
JTC Team
T (US): +1 (908) 824-0775
E: csci@jtcir.com

投资者联系人:
Jenene Thomas
JTC团队
t(美国):+1(908) 824-0775
E: csci@jtcir.com


声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发